Biotech Stocks (IBB) Get Thrown Out with Bath Water
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mail
Biotech Companies sold off today amidst a broader market sell off. But the tumble may have more to do with Regeneron Pharmaceuticals, Inc.'s (NASDAQ: REGN) drug Eylea than the weaker than expected U.S. jobs number.
Regeneron shares tumbled nearly 9 percent on Friday after a survey by Cowen said Eylea was decelerating in terms of patient add-ons. Shares of Regen are up 140 percent so far this year.
Shares of Amgen Inc. (NASDAQ: AMGN) were also lower today, shedding 2.5 percent in what looks like a reaction to the jobs number and general risk aversion.
Regeneron shares tumbled nearly 9 percent on Friday after a survey by Cowen said Eylea was decelerating in terms of patient add-ons. Shares of Regen are up 140 percent so far this year.
Shares of Amgen Inc. (NASDAQ: AMGN) were also lower today, shedding 2.5 percent in what looks like a reaction to the jobs number and general risk aversion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RenaissanceRe Holdings (RNR) PT Raised to $320 at TD Cowen
- SpaceX (SPCX) Buys More Spectrum; TD Cowen Comments
- TD Cowen on Mirum Pharmaceuticals (MIRM): 'We continue to view shares as undervalued'
Create E-mail Alert Related Categories
ETFsRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
